{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:26:35Z","timestamp":1786987595283,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ctrv.2023.102598","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T21:05:36Z","timestamp":1688763936000},"page":"102598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The immunogram of inflammatory breast cancer"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1150-0345","authenticated-orcid":false,"given":"Carmine","family":"Valenza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cristofanilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto T.","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2023.102598_b0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3322\/caac.20082","article-title":"Inflammatory breast cancer: the disease, the biology, the treatment","volume":"60","author":"Robertson","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2023.102598_b0010","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.7150\/jca.23969","article-title":"International consensus on the clinical management of inflammatory breast cancer from the morgan welch inflammatory breast cancer research program 10th anniversary conference","volume":"9","author":"Ueno","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.ctrv.2023.102598_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100220","article-title":"Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)","volume":"6","author":"Dano","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2023.102598_b0020","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41568-018-0010-y","article-title":"Inflammatory breast cancer biology: the tumour microenvironment is key","volume":"18","author":"Lim","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"352","key":"10.1016\/j.ctrv.2023.102598_b0025","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","article-title":"The \u201ccancer immunogram\u201d","volume":"1979","author":"Blank","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2023.102598_b0030","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1158\/2326-6066.CIR-18-0619","article-title":"Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer","volume":"7","author":"Reddy","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2023.102598_b0035","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdt496","article-title":"Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival","volume":"25","author":"Bertucci","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102598_b0040","doi-asserted-by":"crossref","unstructured":"Dirkx AEM, oude Egbrink MGA, Wagstaff J, Griffioen AW. Monocyte\/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 2006;80:1183\u201396. 10.1189\/jlb.0905495.","DOI":"10.1189\/jlb.0905495"},{"key":"10.1016\/j.ctrv.2023.102598_b0045","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.biocel.2013.11.015","article-title":"Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties","volume":"46","author":"Mohamed","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.ctrv.2023.102598_b0050","doi-asserted-by":"crossref","first-page":"e22338","DOI":"10.4161\/onci.22338","article-title":"Plasmacytoid dendritic cells deficient in IFN\u03b1 production promote the amplification of FOXP3 + regulatory T cells and are associated with poor prognosis in breast cancer patients","volume":"2","author":"Sisirak","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2023.102598_b0055","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-12-2549","article-title":"Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets","volume":"19","author":"Van Laere","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102598_b0060","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1929724","article-title":"Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors","volume":"10","author":"Bertucci","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2023.102598_b0065","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1158\/1535-7163.MCT-15-0353","article-title":"Genomic and immunological tumor profiling identifies targetable pathways and extensive CD8+\/PDL1+ immune infiltration in inflammatory breast cancer tumors","volume":"15","author":"Hamm","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2023.102598_b0070","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s11864-023-01069-0","article-title":"Immunotherapy for metastatic triple negative breast cancer: current paradigm and future approaches","volume":"24","author":"Geurts","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ctrv.2023.102598_b0075","doi-asserted-by":"crossref","unstructured":"Bertucci F, Finetti P, Colpaert C, Mamessier E, Parizel M, Dirix L, et al. PD-L1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget 2015;6:13506\u201319. 10.18632\/oncotarget.3642.","DOI":"10.18632\/oncotarget.3642"},{"key":"10.1016\/j.ctrv.2023.102598_b0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13058-019-1108-1","article-title":"Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression","volume":"21","author":"Van Berckelaer","year":"2019","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102598_b0085","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/ajcp\/aqx162","article-title":"Expression of programmed death ligand 1 (PD-L1) in posttreatment primary inflammatory breast cancers and clinical implications","volume":"149","author":"He","year":"2018","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ctrv.2023.102598_b0090","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-018-4834-7","article-title":"The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome","volume":"171","author":"Arias-Pulido","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2023.102598_b0095","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221113269","article-title":"Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer","volume":"14","author":"Pernas","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ctrv.2023.102598_b0100","article-title":"Abstract P4\u201308-19: Biomarker analysis: Multi-omics elucidation of Cohort 1 from a phase II study of a triple combination of Atezolizumab + cobimetinib + eribulin in patients with metastatic inflammatory breast cancer","volume":"83","author":"Lim","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102598_b0105","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3390\/cancers15030767","article-title":"Tumor infiltrating lymphocytes across breast cancer subtypes: current issues for biomarker assessment","volume":"15","author":"Valenza","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2023.102598_b0110","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-P6-01-47","article-title":"Abstract P6\u201301-47: Stromal tumor infiltrating lymphocytes and pathological complete response in patients with inflammatory breast cancer treated with neoadjuvant chemotherapy","volume":"83","author":"De Schepper","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102598_b0115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-021-06391-5","article-title":"Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients","volume":"190","author":"Arias-Pulido","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2023.102598_b0120","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.3390\/cancers13184656","article-title":"The evolution and prognostic role of tumour-infiltrating lymphocytes and peripheral blood-based biomarkers in inflammatory breast cancer patients treated with neoadjuvant chemotherapy","volume":"13","author":"Van Berckelaer","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2023.102598_b0125","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s12094-021-02652-3","article-title":"Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes","volume":"23","author":"Kuroda","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ctrv.2023.102598_b0130","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1158\/0008-5472.CAN-17-2158","article-title":"Inflammatory breast cancer promotes development of M2 tumor-associated macrophages and cancer mesenchymal cells through a complex chemokine network","volume":"79","author":"Valeta-Magara","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102598_b0135","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/path.5415","article-title":"The CD151-midkine pathway regulates the immune microenvironment in inflammatory breast cancer","volume":"251","author":"Hayward","year":"2020","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2023.102598_b0140","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-P1-04-07","article-title":"Abstract P1\u201304-07: Xiap expression is associated with infiltration of cd163+ tumor-associated macrophages in the tumor micro-environment of inflammatory breast cancer","volume":"82","author":"Van Berckelaer","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102598_b0145","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/1471-2407-14-257","article-title":"High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer","volume":"14","author":"Tymoszuk","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2023.102598_b0150","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1200\/JCO.2020.38.15_suppl.3086","article-title":"The spatial localization of CD163+ tumor-associated macrophages predicts prognosis and response to therapy in inflammatory breast cancer","volume":"38","author":"Van Berckelaer","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102598_b0155","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/1878-0261.12621","article-title":"NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers","volume":"14","author":"Bertucci","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctrv.2023.102598_b0160","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13058-018-1007-x","article-title":"Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer","volume":"20","author":"Liang","year":"2018","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102598_b0165","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13058-016-0794-1","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis","volume":"19","author":"Ethier","year":"2017","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102598_b0170","first-page":"106","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","author":"Templeton","year":"2014","journal-title":"JNCI: J National Cancer Institute"},{"key":"10.1016\/j.ctrv.2023.102598_b0175","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.breast.2020.08.006","article-title":"A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer","volume":"53","author":"Van Berckelaer","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2023.102598_b0180","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS19-P3-09-12","article-title":"Abstract P3\u201309-12: Peripheral T cell clonality and exhaustion as novel biomarkers for anti-PD-1 (pembrolizumab) maintenance therapy in patients with metastatic inflammatory breast cancer (mIBC) and non-IBC triple negative breast cancer (mTNBC)","volume":"80","author":"Gao","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102598_b0185","first-page":"7","article-title":"Immune responses to epidermal growth factor receptor (EGFR) and their application for cancer treatment","author":"Sasada","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctrv.2023.102598_b0190","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/annonc\/mdm060","article-title":"Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer","volume":"18","author":"Cabioglu","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102598_b0195","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/annonc\/mdn710","article-title":"Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer","volume":"20","author":"Corkery","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102598_b0200","first-page":"8","article-title":"EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer","author":"Wang","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.ctrv.2023.102598_b0205","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1001\/jamaoncol.2018.1436","article-title":"Safety and efficacy of panitumumab plus neoadjuvant chemotherapy in patients with primary HER2-negative inflammatory breast cancer","volume":"4","author":"Matsuda","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2023.102598_b0210","unstructured":"Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer. ClinicaltrialsGov 2020."},{"key":"10.1016\/j.ctrv.2023.102598_b0215","doi-asserted-by":"crossref","first-page":"e12633","DOI":"10.1200\/JCO.2022.40.16_suppl.e12633","article-title":"Nivolumab with chemotherapy as neoadjuvant treatment for inflammatory breast cancer","volume":"40","author":"Kwa","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102598_b0220","article-title":"Abstract P4\u201308-19: Biomarker analysis: Multi-omics elucidation of Cohort 1 from a phase II study of a triple combination of Atezolizumab + cobimetinib + eribulin in patients with metastatic inflammatory breast cancer","volume":"83","author":"Lim","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102598_b0225","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-P3-02-04","article-title":"Abstract P3\u201302-04: Phase II study of Pembrolizumab Maintenance treatment in patients with HER2-negative inflammatory breast cancer (IBC) and triple-negative breast cancer (TNBC) after response to chemotherapy","volume":"83","author":"Iwase","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102598_b0230","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102598_b0235","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102598_b0240","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102598_b0245","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2023.102598_b0250","unstructured":"EMA. Pembrolizumab 2022. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/keytruda-h-c-003820-ii-0110-epar-assessment-report-variation_en.pdf (accessed December 29, 2022)."},{"key":"10.1016\/j.ctrv.2023.102598_b0255","doi-asserted-by":"crossref","unstructured":"Li J, Xia Y, Wu Q, Zhu S, Chen C, Yang W, et al. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program. Oncotarget 2017;8:49370\u20139. 10.18632\/oncotarget.17217.","DOI":"10.18632\/oncotarget.17217"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223000919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223000919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T01:39:35Z","timestamp":1716946775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737223000919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":51,"alternative-id":["S0305737223000919"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102598","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immunogram of inflammatory breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102598"}}